Nelumal A, the active principle from Ligularia nelumbifolia, is a novel farnesoid X receptor agonist
摘要:
A series of 29 oxyprenylated and azoprenylated phenylpropanoids were chemically synthesized and tested in transfected cultured HepG2 cells by means of the dual-luciferase assay as farnesoid X receptor (FXR) agonists, using the endogenous ligand chenodeoxycholic acid (CDCA) as reference drug. Among the tested molecules, three compounds, namely auraptene, nelumol A, and nelumal A showed a potency comparable to the endogenous ligand, with the latter natural product having a level of activity slightly superior to CDCA. Nelumal A is thus of interest as a valuable potential novel lead compound in the search for FXR agonists. (C) 2012 Elsevier Ltd. All rights reserved.
[EN] SKIN PIGMENTATION MODIFIERS TO DARKEN OR LIGHTEN THE SKIN<br/>[FR] AGENTS DE MODIFICATION DE LA PIGMENTATION DE LA PEAU EN VUE DE L'ASSOMBRIR OU DE L'ÉCLAIRCIR
申请人:AFFICHEM
公开号:WO2016193220A1
公开(公告)日:2016-12-08
The present invention relates to a method for changing the pigmentation of a skin, a mucous membrane or hair with a compound of general formula (I), a cosmetic use of said compound of general formula (I), to cosmetic compositions comprising said compound of general formula (I), and to new depigmenting agents.
The present invention relates to a method for lightening a skin or a mucous membrane with a depigmenting agent, a cosmetic use of said depigmenting agent, to cosmetic compositions comprising said agent, and to new depigmenting agents.
Nelumal A, the active principle from Ligularia nelumbifolia, is a novel farnesoid X receptor agonist
作者:Francesco Epifano、Salvatore Genovese、E. James Squires、Matthew A. Gray
DOI:10.1016/j.bmcl.2012.03.057
日期:2012.5
A series of 29 oxyprenylated and azoprenylated phenylpropanoids were chemically synthesized and tested in transfected cultured HepG2 cells by means of the dual-luciferase assay as farnesoid X receptor (FXR) agonists, using the endogenous ligand chenodeoxycholic acid (CDCA) as reference drug. Among the tested molecules, three compounds, namely auraptene, nelumol A, and nelumal A showed a potency comparable to the endogenous ligand, with the latter natural product having a level of activity slightly superior to CDCA. Nelumal A is thus of interest as a valuable potential novel lead compound in the search for FXR agonists. (C) 2012 Elsevier Ltd. All rights reserved.